CSIMarket Company Name, Ticker, Suppliers, else..
 
Tourmaline Bio Inc   (TRML)
Other Ticker:  
 
 
Price: $19.2700 $1.46 8.198%
Day's High: $19.43 Week Perf: 9.61 %
Day's Low: $ 17.53 30 Day Perf: 42.64 %
Volume (M): 161 52 Wk High: $ 48.31
Volume (M$): $ 3,101 52 Wk Avg: $22.10
Open: $18.07 52 Wk Low: $12.12



 Market Capitalization (Millions $) 496
 Shares Outstanding (Millions) 26
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) 57
 Capital Exp. (TTM) (Millions $) 0

Tourmaline Bio Inc
Tourmaline Bio Inc is a biotechnology company specializing in the development of innovative therapies and diagnostic tools for the detection and treatment of various diseases. The company focuses on utilizing the unique properties of tourmaline, a mineral known for its piezoelectric and pyroelectric properties, to create groundbreaking medical solutions. By harnessing the energy generated by tourmaline crystals, Tourmaline Bio aims to improve the accuracy and effectiveness of diagnostics, as well as enhance drug delivery and tissue regeneration. The company's vision is to revolutionize healthcare by capitalizing on the potential of tourmaline technology in the field of biomedicine.


   Company Address: 27 West 24th Street New York 10010 NY
   Company Phone Number: 481-9832   Stock Exchange / Ticker: NASDAQ TRML


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Groundbreaking Insights into Cardiovascular Health Tourmaline Bio Unveils Phase 2 TRANQUILITY Study at ASPC Congress ...

Published Fri, Aug 2 2024 8:30 PM UTC

''Tourmaline Bio, a pioneering company in developing therapeutics for cardiovascular health, recently unveiled the design of its Phase 2 TRANQUILITY study at the esteemed American Society of Preventive Cardiology (ASPC) Congress 2024. This pivotal event, held in location from start date to end date, gathered leading experts, clinicians, and researchers in the field of cardio...
Clinical Study

' CSIMarket.com ''Abstract' The initiation of Phase 2 clinical trials for TOUR006 marks a significant milestone in cardiovascular disease management. This article explores the implications of Tourmaline Bio's recent advancements, with a particular focus on the TRANQUILITY trial, the mechanisms of TOUR006, and its potential impact on clinical practice.br...

Published Thu, May 16 2024 11:01 AM UTC

'Emerging Therapeutic Frontiers: Tourmaline Bio's TOUR006 as a Potential Game-Changer in Cardiovascular Disease Management'' CSIMarket.com ''Abstract' The initiation of Phase 2 clinical trials for TOUR006 marks a significant milestone in cardiovascular disease management. This article explores the implications of Tourmaline Bio's recent advancements, with a particular focus...
Tourmaline Bio Inc

Tourmaline Bio Inc Surprises Stock Market with Significant Rise in Mar 31 2024 Report Despite Operating Shortfall

Tourmaline Bio Inc has recently announced its financial results for the first quarter of 2024, revealing an operating shortfall of $-17.517 million. While there was no mention of the top-line revenue in the report, it is evident that the company has made significant improvements in its cost-effectiveness compared to the same period last year. This is reflected in the decrease in operating shortfall from $-24.078 million in the first quarter of 2023.
Furthermore, the company reported a decrease in Returns to $-13.311 million from $-22.497 million in the first quarter of 2023. This positive trend indicates that Tourmaline Bio Inc is on track to becoming a successful player in the Healthcare sector.
Tourmaline Bio Inc

Tourmaline Bio Inc Achieves Impressive Operating Income of $4.103 Million in the Fourth Quarter of 2023

Tourmaline Bio Inc, a leading biotechnology and pharmaceutical company, recently announced their operating income for the fourth quarter of 2023, with an impressive figure of $4.103 million. This increase from the same period the previous year is a positive sign for the company and has instilled confidence in analysts about their future performance. The company has shown significant improvement in their net income as well, with an increase from $-18.528 million to $2.126 million in the last fiscal quarter.
Despite a reported deficit of $-42.12 million in the financial period of 2023, Tourmaline Bio Inc has continued to demonstrate their commitment to advancing research and development in the field of immune and inflammatory diseases. The company recently initiated a pivotal Phase 2b trial in Thyroid Eye Disease and expanded their clinical development plan, including accelerating the initiation of a pivotal Phase 3 trial in 2024. This strategic move underscores Tourmaline's dedication to developing transformative medicines for patients in need.
Shares

Tourmaline Bio Raises $150 Million in Successful Public Offering to Advance Revolutionary Medicines for Immune and Inflammatory Diseases

Published Thu, Jan 25 2024 12:00 PM UTC

Tourmaline Bio Announces Successful Pricing of Public Offering of Common Stock
Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company specializing in the development of transformative medicines for patients with immune and inflammatory diseases, made an exciting announcement today. The company revealed the pricing of its underwritten public offeri...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com